ANI Pharmaceuticals, Inc. Logo

ANI Pharmaceuticals, Inc.

ANIP

(1.2)
Stock Price

56,97 USD

3.81% ROA

6.02% ROE

40.62x PER

Market Cap.

1.194.299.379,00 USD

68.04% DER

0% Yield

5.01% NPM

ANI Pharmaceuticals, Inc. Stock Analysis

ANI Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ANI Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 PBV

The stock's PBV ratio (2.09x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 DER

The stock maintains a fair debt to equity ratio (66%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (1.422), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

5 ROE

Negative ROE (-1.42%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-0.86%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

ANI Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ANI Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

ANI Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ANI Pharmaceuticals, Inc. Revenue
Year Revenue Growth
1998 123.061
1999 1 -12306000%
2000 2 50%
2001 1.747.386 100%
2002 2.833.851 38.34%
2003 65.494 -4226.89%
2004 77.886 15.91%
2005 258.351 69.85%
2006 14.438.621 98.21%
2007 493.054 -2828.41%
2008 3.780.829 86.96%
2009 1.258.054 -200.53%
2010 2.474.237 49.15%
2011 435.160 -468.58%
2012 2.300.736 81.09%
2013 30.082.000 92.35%
2014 55.970.000 46.25%
2015 76.322.000 26.67%
2016 128.622.000 40.66%
2017 176.842.000 27.27%
2018 201.576.000 12.27%
2019 206.547.000 2.41%
2020 208.475.000 0.92%
2021 216.136.000 3.54%
2022 316.385.000 31.69%
2023 527.316.000 40%
2023 486.816.000 -8.32%
2024 552.160.000 11.83%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ANI Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 1.400.129
1999 660.588 -111.95%
2000 1.887.832 65.01%
2001 2.141.944 11.86%
2002 4.786.818 55.25%
2003 3.691.420 -29.67%
2004 9.162.439 59.71%
2005 6.409.080 -42.96%
2006 3.855.660 -66.23%
2007 4.751.313 18.85%
2008 15.789.980 69.91%
2009 13.680.573 -15.42%
2010 39.705.502 65.54%
2011 44.182.260 10.13%
2012 16.888.849 -161.61%
2013 1.712.000 -886.5%
2014 2.678.000 36.07%
2015 2.874.000 6.82%
2016 2.906.000 1.1%
2017 9.070.000 67.96%
2018 15.388.000 41.06%
2019 19.806.000 22.31%
2020 16.001.000 -23.78%
2021 11.369.000 -40.74%
2022 22.318.000 49.06%
2023 44.484.000 49.83%
2023 34.286.000 -29.74%
2024 29.184.000 -17.48%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ANI Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 1.112.647
1999 853.389 -30.38%
2000 1.678.581 49.16%
2001 2.298.659 26.98%
2002 1.765.624 -30.19%
2003 2.327.090 24.13%
2004 3.080.135 24.45%
2005 3.050.555 -0.97%
2006 7.025.418 56.58%
2007 4.331.361 -62.2%
2008 5.961.354 27.34%
2009 5.673.561 -5.07%
2010 5.940.360 4.49%
2011 6.981.490 14.91%
2012 8.229.523 15.17%
2013 16.388.000 49.78%
2014 17.935.000 8.63%
2015 21.156.000 15.22%
2016 27.829.000 23.98%
2017 31.580.000 11.88%
2018 44.063.000 28.33%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ANI Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
1998 -2.519.646
1999 -1.513.976 -66.43%
2000 -3.542.121 57.26%
2001 -2.675.217 -32.4%
2002 -3.718.591 28.06%
2003 -5.953.016 37.53%
2004 -12.164.688 51.06%
2005 -8.451.284 -43.94%
2006 4.634.375 282.36%
2007 -8.589.620 153.95%
2008 -17.970.505 52.2%
2009 -29.321.437 38.71%
2010 -41.527.938 29.39%
2011 -50.770.163 18.2%
2012 -22.904.097 -121.66%
2013 1.703.000 1444.93%
2014 24.044.000 92.92%
2015 39.641.000 39.35%
2016 49.033.000 19.15%
2017 57.215.000 14.3%
2018 68.551.000 16.54%
2019 60.810.000 -12.73%
2020 28.574.000 -112.82%
2021 14.740.000 -93.85%
2022 31.908.000 53.8%
2023 122.244.000 73.9%
2023 109.320.000 -11.82%
2024 80.900.000 -35.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ANI Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
1998 123.061
1999 1 -12306000%
2000 24.292 100%
2001 1.747.386 98.61%
2002 2.833.851 38.34%
2003 65.494 -4226.89%
2004 77.886 15.91%
2005 258.351 69.85%
2006 14.438.621 98.21%
2007 493.054 -2828.41%
2008 3.780.829 86.96%
2009 1.258.054 -200.53%
2010 2.205.487 42.96%
2011 385.160 -472.62%
2012 -6.866.264 105.61%
2013 20.108.000 134.15%
2014 44.497.000 54.81%
2015 63.630.000 30.07%
2016 79.842.000 20.31%
2017 97.810.000 18.37%
2018 128.552.000 23.91%
2019 143.393.000 10.35%
2020 121.318.000 -18.2%
2021 115.526.000 -5.01%
2022 177.600.000 34.95%
2023 334.912.000 46.97%
2023 245.512.000 -36.41%
2024 262.580.000 6.5%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ANI Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
1998 -2.659.415
1999 -1.406.259 -89.11%
2000 -3.437.195 59.09%
2001 -2.611.361 -31.62%
2002 -3.810.690 31.47%
2003 -5.959.354 36.06%
2004 -12.016.207 50.41%
2005 -9.651.036 -24.51%
2006 2.791.273 445.76%
2007 -7.584.435 136.8%
2008 -17.425.178 56.47%
2009 -47.527.768 63.34%
2010 -46.196.216 -2.88%
2011 -51.608.504 10.49%
2012 -27.717.739 -86.19%
2013 301.000 9308.55%
2014 28.747.000 98.95%
2015 15.375.000 -86.97%
2016 3.934.000 -290.82%
2017 -1.076.000 465.61%
2018 15.494.000 106.94%
2019 6.094.000 -154.25%
2020 -22.548.000 127.03%
2021 -42.603.000 47.07%
2022 -47.896.000 11.05%
2023 39.760.000 220.46%
2023 18.779.000 -111.73%
2024 -9.148.000 305.28%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ANI Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -27
1999 -10 -170%
2000 -22 52.38%
2001 -15 -50%
2002 -18 22.22%
2003 -19 5.26%
2004 -25 24%
2005 -18 -47.06%
2006 5 525%
2007 -11 140%
2008 -23 54.55%
2009 -50 56%
2010 -25 -100%
2011 -19 -38.89%
2012 -8 -157.14%
2013 -1 0%
2014 3 100%
2015 1 -100%
2016 0 0%
2017 0 0%
2018 1 100%
2019 1 0%
2020 -2 100%
2021 -3 66.67%
2022 -3 -50%
2023 2 300%
2023 1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ANI Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
1998 -3.166.409
1999 -1.792.041 -76.69%
2000 -3.250.842 44.87%
2001 -1.910.555 -70.15%
2002 -4.001.485 52.25%
2003 -5.530.857 27.65%
2004 -10.545.647 47.55%
2005 -8.364.925 -26.07%
2006 -5.035.990 -66.1%
2007 710.564 808.73%
2008 -16.187.048 104.39%
2009 -18.596.634 12.96%
2010 -40.160.947 53.69%
2011 -48.590.028 17.35%
2012 -25.894.213 -87.65%
2013 -5.675.000 -356.29%
2014 -13.721.000 58.64%
2015 -15.419.000 11.01%
2016 -121.588.000 87.32%
2017 -68.574.000 -77.31%
2018 56.162.000 222.1%
2019 18.082.000 -210.6%
2020 -53.055.000 134.08%
2021 -20.316.000 -161.15%
2022 -47.658.000 57.37%
2023 100.448.000 147.45%
2023 27.616.000 -263.73%
2024 12.965.000 -113%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ANI Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 -3.041.425
1999 -1.787.822 -70.12%
2000 -3.207.604 44.26%
2001 -1.823.820 -75.87%
2002 -3.962.493 53.97%
2003 -5.521.992 28.24%
2004 -10.442.443 47.12%
2005 -8.297.509 -25.85%
2006 -4.996.735 -66.06%
2007 739.992 775.24%
2008 -15.535.932 104.76%
2009 -18.430.910 15.71%
2010 -40.097.506 54.03%
2011 -47.870.103 16.24%
2012 -25.283.020 -89.34%
2013 -5.484.000 -361.03%
2014 22.033.000 124.89%
2015 17.264.000 -27.62%
2016 27.472.000 37.16%
2017 39.419.000 30.31%
2018 67.074.000 41.23%
2019 45.631.000 -46.99%
2020 15.267.000 -198.89%
2021 3.322.000 -359.57%
2022 -31.203.000 110.65%
2023 118.959.000 126.23%
2023 32.169.000 -269.79%
2024 17.414.000 -84.73%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ANI Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 124.984
1999 4.219 -2862.41%
2000 43.238 90.24%
2001 86.735 50.15%
2002 38.992 -122.44%
2003 8.865 -339.84%
2004 103.204 91.41%
2005 67.416 -53.09%
2006 39.255 -71.74%
2007 29.428 -33.39%
2008 651.116 95.48%
2009 165.724 -292.89%
2010 63.441 -161.23%
2011 719.925 91.19%
2012 611.193 -17.79%
2013 191.000 -220%
2014 35.754.000 99.47%
2015 32.683.000 -9.4%
2016 149.060.000 78.07%
2017 107.993.000 -38.03%
2018 10.912.000 -889.67%
2019 27.549.000 60.39%
2020 68.322.000 59.68%
2021 23.638.000 -189.03%
2022 16.455.000 -43.65%
2023 18.511.000 11.11%
2023 4.553.000 -306.57%
2024 4.449.000 -2.34%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ANI Pharmaceuticals, Inc. Equity
Year Equity Growth
1998 2.631.430
1999 5.450.514 51.72%
2000 2.125.654 -156.42%
2001 4.051.480 47.53%
2002 4.623.585 12.37%
2003 8.684.265 46.76%
2004 15.920.606 45.45%
2005 6.818.838 -133.48%
2006 18.071.231 62.27%
2007 29.725.492 39.21%
2008 13.826.419 -114.99%
2009 15.830.394 12.66%
2010 19.147.122 17.32%
2011 37.815.292 49.37%
2012 28.175.505 -34.21%
2013 40.962.000 31.22%
2014 139.785.000 70.7%
2015 160.082.000 12.68%
2016 169.648.000 5.64%
2017 174.756.000 2.92%
2018 197.263.000 11.41%
2019 212.791.000 7.3%
2020 195.700.000 -8.73%
2021 358.740.000 45.45%
2022 338.540.000 -5.97%
2023 454.711.000 25.55%
2023 432.749.000 -5.07%
2024 455.760.000 5.05%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ANI Pharmaceuticals, Inc. Assets
Year Assets Growth
1998 3.449.345
1999 5.779.629 40.32%
2000 3.066.917 -88.45%
2001 4.979.242 38.41%
2002 5.879.804 15.32%
2003 9.565.470 38.53%
2004 17.827.361 46.34%
2005 9.574.554 -86.2%
2006 22.370.840 57.2%
2007 31.241.342 28.39%
2008 17.679.371 -76.71%
2009 36.436.928 51.48%
2010 44.766.650 18.61%
2011 62.379.755 28.24%
2012 38.769.170 -60.9%
2013 44.500.000 12.88%
2014 263.709.000 83.13%
2015 285.265.000 7.56%
2016 322.864.000 11.65%
2017 412.138.000 21.66%
2018 430.604.000 4.29%
2019 456.789.000 5.73%
2020 461.190.000 0.95%
2021 771.598.000 40.23%
2022 760.087.000 -1.51%
2023 889.914.000 14.59%
2023 904.422.000 1.6%
2024 920.753.000 1.77%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ANI Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
1998 817.915
1999 329.115 -148.52%
2000 941.263 65.03%
2001 927.762 -1.46%
2002 1.256.219 26.15%
2003 881.205 -42.56%
2004 1.906.755 53.79%
2005 2.755.716 30.81%
2006 4.299.609 35.91%
2007 1.515.850 -183.64%
2008 3.852.952 60.66%
2009 20.606.534 81.3%
2010 25.619.528 19.57%
2011 24.564.463 -4.3%
2012 10.593.665 -131.88%
2013 3.538.000 -199.43%
2014 123.924.000 97.15%
2015 125.183.000 1.01%
2016 153.216.000 18.3%
2017 237.382.000 35.46%
2018 233.341.000 -1.73%
2019 243.998.000 4.37%
2020 265.490.000 8.1%
2021 412.858.000 35.69%
2022 421.547.000 2.06%
2023 435.203.000 3.14%
2023 471.673.000 7.73%
2024 464.993.000 -1.44%

ANI Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
27.89
Net Income per Share
1.4
Price to Earning Ratio
40.62x
Price To Sales Ratio
2.22x
POCF Ratio
9.75
PFCF Ratio
12.67
Price to Book Ratio
2.41
EV to Sales
2.35
EV Over EBITDA
12.11
EV to Operating CashFlow
11.23
EV to FreeCashFlow
13.42
Earnings Yield
0.02
FreeCashFlow Yield
0.08
Market Cap
1,19 Bil.
Enterprise Value
1,26 Bil.
Graham Number
27.24
Graham NetNet
-1.59

Income Statement Metrics

Net Income per Share
1.4
Income Quality
4.47
ROE
0.06
Return On Assets
0.03
Return On Capital Employed
0.06
Net Income per EBT
0.76
EBT Per Ebit
0.75
Ebit per Revenue
0.09
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.53
Operating Profit Margin
0.09
Pretax Profit Margin
0.07
Net Profit Margin
0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.06
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
5.83
Free CashFlow per Share
4.88
Capex to Operating CashFlow
0.16
Capex to Revenue
0.03
Capex to Depreciation
0.31
Return on Invested Capital
0.05
Return on Tangible Assets
0.04
Days Sales Outstanding
112.48
Days Payables Outstanding
70.24
Days of Inventory on Hand
181.02
Receivables Turnover
3.24
Payables Turnover
5.2
Inventory Turnover
2.02
Capex per Share
0.95

Balance Sheet

Cash per Share
12,79
Book Value per Share
23,59
Tangible Book Value per Share
12.65
Shareholders Equity per Share
23.59
Interest Debt per Share
17.15
Debt to Equity
0.68
Debt to Assets
0.34
Net Debt to EBITDA
0.67
Current Ratio
3.97
Tangible Asset Value
0,24 Bil.
Net Current Asset Value
0,09 Bil.
Invested Capital
678121000
Working Capital
0,42 Bil.
Intangibles to Total Assets
0.23
Average Receivables
0,17 Bil.
Average Payables
0,05 Bil.
Average Inventory
119642500
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ANI Pharmaceuticals, Inc. Dividends
Year Dividends Growth

ANI Pharmaceuticals, Inc. Profile

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

CEO
Mr. Nikhil Lalwani
Employee
642
Address
210 Main Street West
Baudette, 56623

ANI Pharmaceuticals, Inc. Executives & BODs

ANI Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Chad Gassert
Senior Vice President of Corporate Development & Strategy
70
2 Ms. Meredith W. Cook
Senior Vice President, General Counsel & Corporate Secretary
70
3 Ms. Krista L. Davis
Senior Vice President & Chief Human Resources Officer
70
4 Ms. Elizabeth Powell J.D.
Chief Compliance Officer & Head of Legal of Rare Disease
70
5 Mr. Nikhil Lalwani
President, Chief Executive Officer & Director
70
6 Mr. Ori Gutwerg
Senior Vice President of Generics
70
7 Mr. James G. Marken
Senior Vice President of Operations
70
8 Mr. Stephen P. Carey
Senior Vice President of Finance & Chief Financial Officer
70
9 Mr. Christopher K. Mutz
Senior Vp & Head of Rare Disease
70
10 Mr. Muthusamy Shanmugam MS R.Ph.
Head of R&D, Chief Operating Officer of Novitium Operations & Director
70

ANI Pharmaceuticals, Inc. Competitors